IMMUNE NETWORK

  • 제10권3호
  • /
  • Pages.81-84
  • /
  • 2010
  • /
  • 1598-2629(pISSN)
  • /
  • 2092-6685(eISSN)
대한면역학회 (The Korean Association of Immunobiologists)
권호 표지
DOI QR코드

DOI QR Code

The Role of B Cells in Transplantation and Immunopathic Diseases

  • Basten, A. (Garvan Institute)
  • 투고 : 2010.06.04
  • 심사 : 2010.06.11
  • 발행 : 2010.06.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

B cells, by virtue of their diverse roles in immune responses to foreign and self antigens, have become of increasing interest to the clinician as well as the basic immunologist. In particular, it is now apparent that the development of B cell unresponsiveness in antibody and T cell mediated autoimmune disorders and the transplant setting is both worthwhile and achievable.

키워드

참고문헌

  1. Basten A, Brink R. Tolerance and Autoimmunity: B cells. In: Rose NR, Mackay IR, editors. The Autoimmune Diseases. 4th ed. St. Louis: Academic Press; p167-177, 2006
  2. Goodnow CC: Multistep pathogenesis of autoimmune disease. Cell 130:25-35, 2007 https://doi.org/10.1016/j.cell.2007.06.033
  3. von Boehmer H, Melchers F: Checkpoints in lymphocyte development and autoimmune disease. Nat Immunol 11:14-20, 2010 https://doi.org/10.1038/ni.1794
  4. von Boehmer H, Melchers F: Checkpoints in lymphocyte development and autoimmune disease. Nat Immunol 11:14-20, 2010 https://doi.org/10.1038/ni.1794
  5. Phan TG, Gray EE, Cyster JG: The microanatomy of B cell activation. Curr Opin Immunol 21:258-265, 2009 https://doi.org/10.1016/j.coi.2009.05.006
  6. Cox SL, Silveira PA: Emerging roles for B lymphocytes in Type 1 diabetes. Expert Rev Clin Immu 5:311-324, 2009 https://doi.org/10.1586/eci.09.4
  7. Singh A, Carson WF 1th, Secor ER Jr, Guernsey LA, Flavell RA, Clark RB, Thrall RS, Schramm CM: Regulatory role of B cells in a murine model of allergic airway disease. J Immunol 180:7318-7326, 2008 https://doi.org/10.4049/jimmunol.180.11.7318
  8. Yanaba K, Bouaziz JD, Matsushita T, Magro CM, St Clair EW, Tedder TF: B-lymphocyte contributions to human autoimmune disease. Immunol Rev 223:284-299, 2008 https://doi.org/10.1111/j.1600-065X.2008.00646.x
  9. DiLillo DJ, Matsushita T, Tedder TF: B10 cells and regulatory B cells balance immune responses during inflammation, autoimmunity, and cancer. Ann N Y Acad Sci 1183:38-57, 2010 https://doi.org/10.1111/j.1749-6632.2009.05137.x
  10. Blair PA, Norena LY, Flores-Borja F, Rawlings DJ, Isenberg DA, Ehrenstein MR, Mauri C: CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. Immunity 32:129-140, 2010 https://doi.org/10.1016/j.immuni.2009.11.009
  11. Skupsky J, Zhang AH, Su Y, Scott DW: B-cell-delivered gene therapy induces functional T regulatory cells and leads to a loss of antigen-specific effector cells. Mol Ther 2010 [Epub ahead of print]
  12. Silveira PA, Dombrowsky J, Johnson E, Chapman HD, Nemazee D, Serreze DV: B cell selection defects underlie the development of diabetogenic APCs in nonobese diabetic mice. J Immunol 172:5086-5094, 2004 https://doi.org/10.4049/jimmunol.172.8.5086
  13. Gavanescu I, Benoist C, Mathis D: B cells are required for Aire-deficient mice to develop multi-organ autoinflammation: a therapeutic approach for APECED patients. Pro Natl Acad Sci U S A 105:13009-13014, 2008 https://doi.org/10.1073/pnas.0806874105
  14. Browning JL: B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nat Rev Drug Discov 5:564-576, 2006 https://doi.org/10.1038/nrd2085
  15. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T: Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N EnglJ Med 350:2572-2581, 2004 https://doi.org/10.1056/NEJMoa032534
  16. Jacobi AM, Dorner T: Current aspects of anti-CD20 therapy in rheumatoid arthritis. Curr Opin Pharmacol 2010 [Epub ahead of print]
  17. Lee YH, Bae SC, Song GG: The efficacy and safety of rituximab for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials. Rheumatol Int 2010 [Epub ahead of print]
  18. Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, Utset TO, Gordon C, Isenberg DA, Hsieh HJ, Zhang D, Brunetta PG: Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 62:222-233, 2010 https://doi.org/10.1002/art.27233
  19. Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, Bar-Or A, Panzara M, Sarkar N, Agarwal S, Langer-Gould A, Smith CH, HERMES Trial Group: B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358:676-688, 2008 https://doi.org/10.1056/NEJMoa0706383
  20. Bingham CO 3rd, Looney RJ, Deodhar A, Halsey N, Greenwald M, Codding C, Trzaskoma B, Martin F, Agarwal S, Kelman A: Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum 62:64-74, 2010 https://doi.org/10.1002/art.25034
  21. Kessel A, Rosner I, Toubi E: Rituximab: beyond simple B cell depletion. Clin Rev Allergy Immunol 34:74-79, 2008 https://doi.org/10.1007/s12016-008-8074-1
  22. Marino E, Villanueva J, Walters S, Liuwantara D, Mackay F, Grey ST: CD4(+)CD25(+) T-cells control autoimmunity in the absence of B-cells. Diabetes 58:1568-1577, 2009 https://doi.org/10.2337/db08-1504
  23. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, Becker DJ, Gitelman SE, Goland R, Gottlieb PA, Marks JB, McGee PF, Moran AM, Raskin P, Rodriguez H, Schatz DA, Wherrett D, Wilson DM, Lachin JM, Skyler JS, Type 1 Diabetes TrialNet Anti-CD20 Study Group: Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Eng J Med 361:2143-2152, 2009 https://doi.org/10.1056/NEJMoa0904452
  24. Thaunat O, Morelon E, Defrance T: Am"B"valent: anti-CD20 antibodies unravel the dual role of B cells in immunopathogenesis. Blood 2010 [Epub ahead of print]
  25. Ratanatharathorn V, Pavletic S, Uberti JP: Clinical applications of rituximab in allogeneic stem cell transplantation: anti- tumor and immunomodulatory effects. Cancer Treat Rev 35:653-661, 2009 https://doi.org/10.1016/j.ctrv.2009.07.004
  26. Guidelines for clinical usage of intravenous immunoglobulin IVIg in Australia. National Blood Authority, Australia. pp 160-165, 2008
  27. Parsons RF, Vivek K, Redfield RR, Migone TS, Cancro MP, Naji A, Noorchashm H: B-cell tolerance in transplantation: is repertoire remodeling the answer? Expert Rev Clin Immunol 5:703, 2009 https://doi.org/10.1586/eci.09.63
  28. Fan X, Ang A, Pollock-Barziv SM, Dipchand AI, Ruiz P, Wilson G, Platt JL, West LJ: Donor-specific B-cell tolerance after ABO-incompatible infant heart transplantation. Nat Med 10:1227-1233, 2004 https://doi.org/10.1038/nm1126
  29. Gibbons C, Sykes M: Manipulating the immune system for anti-tumor responses and transplant tolerance via mixed hematopoietic chimerism. Immunol Rev 223:334-360, 2008 https://doi.org/10.1111/j.1600-065X.2008.00636.x
  30. Zarkhin V, Kambham N, Li L, Kwok S, Hsieh SC, Salvatierra O, Sarwal MM: Characterization of intra-graft B cells during renal allograft rejection. Kidney Int 74:664-673, 2008 https://doi.org/10.1038/ki.2008.249
  31. Zarkhin V, Li L, Kambham N, Sigdel T, Salvatierra O, Sarwal MM: A randomized, prospective trial of rituximab for acute rejection in pediatric renal transplantation. Am J Transplant 8:2607-2617, 2008 https://doi.org/10.1111/j.1600-6143.2008.02411.x
  32. Liu C, Noorchashm H, Sutter JA, Naji M, Prak EL, Boyer J, Green T, Rickels MR, Tomaszewski JE, Koeberlein B, Wang Z, Paessler ME, Velidedeoglu E, Rostami SY, Yu M, Barker CF, Naji A: B lymphocyte-directed immunotherapy promotes long-term islet allograft survival in nonhuman primates. Nat Med 13:1295-1298, 2007 https://doi.org/10.1038/nm1673
  33. Terasaki PI, Ozawa M, Castro R: Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival. Am J Transplant 7:408-415, 2007 https://doi.org/10.1111/j.1600-6143.2006.01644.x
  34. Turka LA, Lechler RI: Towards the identification of biomarkers of transplantation tolerance. Nat Rev Immunol 9:521-526, 2009 https://doi.org/10.1038/nri2568
  35. Barnett JC, Bean SM, Whitaker RS, Kondoh E, Baba T, Fujii S, Marks JR, Dressman HK, Murphy SK, Berchuck A: Ovarian cancer tumor infiltrating T-regulatory (T(reg)) cells are associated with a metastatic phenotype. Gynecol Oncol 116: 556-562, 2010 https://doi.org/10.1016/j.ygyno.2009.11.020
  36. Xu L, Xu W, Qiu S, Xiong S: Enrichment of CCR6+Foxp3+ regulatory T cells in the tumor mass correlates with impaired CD8+ T cell function and poor prognosis of breast cancer. Clin Immunol 135:466-475, 2010 https://doi.org/10.1016/j.clim.2010.01.014
  37. Zhang HH, Mei MH, Fei R, Liao WJ, Wang XY, Qin LL, Wang JH, Wei L, Chen HS: Regulatory T cell depletion enhances tumor specific CD8 T-cell responses, elicited by tumor antigen NY-ESO-1b in hepatocellular carcinoma patients, in vitro. Int J Oncol 36:841-848, 2010

피인용 문헌

  1. Evaluation of Immunotoxicity of Shizukaol B Isolated from Chloranthus japonicus vol.19, pp.1, 2010, https://doi.org/10.4062/biomolther.2011.19.1.059